Navigation Links
Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
Date:5/14/2009

ify or obtain rights to new products; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2009 (File No. 001-34186). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... GenoCAD, a leading provider ... version of its flagship DNA design platform, which has been enhanced to boost ... numerous genetic parts, which in turn can be recombined using specific sets of ...
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... million. The orders are for air emission abatement projects in ... is a large order for a municipality in the ... replacing a competitor,s system that failed to meet the customer,s ... solutions," said Derek S. Webb , President and Chief ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.17 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has announced ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Middle East & Africa Biomedical ... at a CAGR of 3.26% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
Breaking Biology Technology:GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2
... Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today ... an additional 180 days to regain compliance with NASDAQ,s $1.00 ... on May 3, 2010, CTI was notified by NASDAQ that ... for continued listing and was provided until November 1, 2010 ...
... Nov. 2, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has granted marketing approval for ... formulation of acetaminophen to be approved in the United ... to moderate pain, the management of moderate to severe ...
... 2, 2010 Modern Plastics offers SUSTARIN® C ... manufactured by ROCHLING Engineering Plastics. The technology ... sheet and rod are free of centerline or core ... stability for close tolerance parts. A low coefficient of ...
Cached Biology Technology:NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule 2Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 2Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 3Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 4Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 5Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 6Modern Plastics SUSTARIN® C (Acetal) Product Uses Special Manufacturing Technology to Ensure Every Sheet and Rod Are Free of Centerline or Core Porosity 2
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... the short end of the stick, in this case the ... at the ends of chromosomes, can be thought of as ... neighboring chromosomes. It is typical for telomeres to ... a new study from Brigham and Women,s Hospital (BWH) suggest ...
... to the way scientists name new plants that took effect ... Latin requirement - a stipulation that descriptions or diagnoses of ... rules make it possible to take full advantage of an ... particular species is indeed new to science: Many studies now ...
... 2012Healthy individuals who carry a gene variation linked to ... their brains that may help explain how the gene ... results of this innovative brain imaging study are described ... Brain Connectivity, a bimonthly peer-reviewed publication from Mary ...
Cached Biology News:The long, err, short of it 2
Human Glypican 2 Biotinylated Affinity Purified PAb...
B2-Microgloulin...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
...
Biology Products: